Mithra Obtains Three Marketing Authorisations for its Product Tibelia®, one of Which in the United Kingdom Where it Signed a First License and Supply Agreement

  • Mithra already obtained three Marketing Authorisations for its product Tibelia® in United Kingdom, Norway and Sweden.
  • These MA’s occur just a few weeks after the successful closure of the two decentralized procedures providing a green light in 14 European countries. Still 11 Marketing Authorisations to come in the next few weeks and months.
  • Mithra already signed an exclusive License and Supply Agreement with Mercury in the United Kingdom, the fourth biggest potential of the global tibolone market in terms of volume (nearly 14 million tablets in 2015).
  • Tibelia should be available on the UK market in the next few months.

Liège, Belgium 13 April 2016 – Mithra Pharmaceuticals announces today that it obtained three Markering Authorisations for the commercialisation of its product Tibelia® (a product which is bioequivalent to Livial® and developed in-house) in the territories of United Kingdom, Norway and Sweden. These authorisations occur just a few weeks after the successful closure of the two decentralized procedures providing a green light in 14 European countries. There are thus still 11 Marketing Authorisations to come in the next few weeks and months.

Read the Press Release